Spatial intra‐tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co‐clinical cancer studies
Abstract Targeted therapy in the treatment of cancer has produced great clinical successes. However, with these came the challenge of acquired resistance. Melanoma, a cancer that carries one of the highest mutational burdens, displays great complexity in mutational acquired resistance with a notable...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2015-07-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.201505431 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849342558468046848 |
|---|---|
| author | Claudia Wellbrock |
| author_facet | Claudia Wellbrock |
| author_sort | Claudia Wellbrock |
| collection | DOAJ |
| description | Abstract Targeted therapy in the treatment of cancer has produced great clinical successes. However, with these came the challenge of acquired resistance. Melanoma, a cancer that carries one of the highest mutational burdens, displays great complexity in mutational acquired resistance with a notable degree of inter‐tumoural heterogeneity. In this issue of EMBO Molecular Medicine, Kemper et al (2015) describe the identification of multiple, partly novel resistance mechanisms present in one patient and within a single metastasis, where one mutation could be traced back to a pre‐treatment lesion. Importantly, the observed intra‐tumoural “spatial” heterogeneity can impact on the interpretability of patient‐derived xenografts, and this might have implications particularly for co‐clinical treatment studies. |
| format | Article |
| id | doaj-art-db695f001b144c349e4c32f0ca699cb9 |
| institution | Kabale University |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2015-07-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-db695f001b144c349e4c32f0ca699cb92025-08-20T03:43:21ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842015-07-01791087108910.15252/emmm.201505431Spatial intra‐tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co‐clinical cancer studiesClaudia Wellbrock0Manchester Cancer Research Centre, Wellcome Trust Centre for Cell‐Matrix Research, University of ManchesterAbstract Targeted therapy in the treatment of cancer has produced great clinical successes. However, with these came the challenge of acquired resistance. Melanoma, a cancer that carries one of the highest mutational burdens, displays great complexity in mutational acquired resistance with a notable degree of inter‐tumoural heterogeneity. In this issue of EMBO Molecular Medicine, Kemper et al (2015) describe the identification of multiple, partly novel resistance mechanisms present in one patient and within a single metastasis, where one mutation could be traced back to a pre‐treatment lesion. Importantly, the observed intra‐tumoural “spatial” heterogeneity can impact on the interpretability of patient‐derived xenografts, and this might have implications particularly for co‐clinical treatment studies.https://doi.org/10.15252/emmm.201505431 |
| spellingShingle | Claudia Wellbrock Spatial intra‐tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co‐clinical cancer studies EMBO Molecular Medicine |
| title | Spatial intra‐tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co‐clinical cancer studies |
| title_full | Spatial intra‐tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co‐clinical cancer studies |
| title_fullStr | Spatial intra‐tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co‐clinical cancer studies |
| title_full_unstemmed | Spatial intra‐tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co‐clinical cancer studies |
| title_short | Spatial intra‐tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co‐clinical cancer studies |
| title_sort | spatial intra tumour heterogeneity in acquired resistance to targeted therapy complicates the use of pdx models for co clinical cancer studies |
| url | https://doi.org/10.15252/emmm.201505431 |
| work_keys_str_mv | AT claudiawellbrock spatialintratumourheterogeneityinacquiredresistancetotargetedtherapycomplicatestheuseofpdxmodelsforcoclinicalcancerstudies |